Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tiniest flu patients: IV zanamivir tested in infants under 6 months

NCT ID NCT04494412

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study investigates the safety and how the body processes intravenous (IV) zanamivir in hospitalized infants under 6 months old with complicated influenza. Currently, no antiviral is approved for this age group, leaving them vulnerable. The trial will measure drug levels in the blood and monitor for side effects over up to 24 days, with treatment lasting up to 10 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanamivir
What this could lead to
If successful, this could provide a safe and effective antiviral treatment option for very young infants hospitalized with severe influenza.
What could go wrong
This is a small, early-phase study with only 8 participants, so results may not apply broadly. The drug's safety and effectiveness in this age group are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRALGIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arthralgia influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRALGIA INFLUENZA, HUMAN

Contacts and locations

Locations

  • GSK Investigational Site

    Florence, 50139, Italy

  • GSK Investigational Site

    Messina, Italy

  • GSK Investigational Site

    Roma, 00165, Italy

  • GSK Investigational Site

    Bydgoszcz, 85-168, Poland

  • GSK Investigational Site

    Barcelona, 08950, Spain

  • GSK Investigational Site

    Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.